Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Diabetes mellitus, type 2 Draft recommendations posted for stakeholder feedback: April 18, 2024 End of feedback period: May 03, 2024 Draft Recommendation
Therapeutic Area: Psoriatic arthritis Draft recommendations posted for stakeholder feedback: April 18, 2024 End of feedback period: May 03, 2024 Draft Recommendation
Therapeutic Area: Ankylosing spondylitis Draft recommendations posted for stakeholder feedback: April 18, 2024 End of feedback period: May 03, 2024 Draft Recommendation